Virology & Immunology Journal最新文献

{"title":"Precision Medicine and Artificial Intelligence: Challenges and Potential in the Post-Human Genome Era","authors":"Mirijello M","doi":"10.23880/vij-16000322","DOIUrl":"https://doi.org/10.23880/vij-16000322","url":null,"abstract":"","PeriodicalId":334586,"journal":{"name":"Virology & Immunology Journal","volume":"14 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117119447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of the Multicriteria Decision Making Method in Establishing the Consequences of Breast Cancer Treatment","authors":"Cvetkovic J","doi":"10.23880/vij-16000316","DOIUrl":"https://doi.org/10.23880/vij-16000316","url":null,"abstract":"Objective: We present in this paper the results of multicriteria ranking of risk factors for depression, anxiety and stress in women with breast cancer. Method: The PROMETHEE/GAIA method was used for ranking purposes, with additional optimization of alternatives using the PROMETHEE method with inherent limitations. Results: Almost 50% of women with early breast cancer experienced depression, anxiety or both in the period of one year after the diagnosis; 25% in the second, third and fourth year; and 15% in the fifth year. Long-term depression and anxiety were associated with prior psychological treatment, absence of an intimate, confident relationship, younger age and severely stressful (non-cancer) events in life. A lack of intimate support in confidence also predicted prolonged episodes of depression and anxiety. Conclusion: Increased levels of depression, anxiety or both in the first year after the diagnosis of early breast cancer indicate the need for special support services during that period. Psychological intervention for women with breast cancer who no longer have the disease should take into account a broader social context of cancer occurrence, with a focus on the improvement of social support.","PeriodicalId":334586,"journal":{"name":"Virology & Immunology Journal","volume":"30 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133059331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic Drug Targets for Covid-19","authors":"Yalcin S","doi":"10.23880/vij-16000325","DOIUrl":"https://doi.org/10.23880/vij-16000325","url":null,"abstract":"COVID-19 pandemic is a respiratory disease that has spread in many countries worldwide and has become a significant health problem. Caused by the virus called SARS-CoV-2, this disease typically manifests with symptoms such as fever, cough, shortness of breath, fatigue, and muscle aches. Various approaches are used in the treatment of COVID-19, including antiviral drugs, respiratory support, anti-inflammatory drugs, and antibody therapies. Antiviral drugs like remdesivir, in particular, are used to alleviate the course of the disease and expedite the recovery process. Vaccination programs are also becoming widespread globally, playing a crucial role in controlling the spread of the disease. The treatment of COVID-19 requires a global effort, and health authorities and scientists are continuously working on new treatment options and measures. This review study focuses on potential drug targets in the treatment process of COVID-19. It discusses the effects of some researched drugs as well as certain components derived from natural sources such as plants, microorganisms, and algae with pharmaceutical potential. However, further research and development of effective treatment methods are still needed for the treatment of COVID-19.","PeriodicalId":334586,"journal":{"name":"Virology & Immunology Journal","volume":"81 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139361540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Strategies to Combat Japanese Encephalitis","authors":"Singh N","doi":"10.23880/vij-16000328","DOIUrl":"https://doi.org/10.23880/vij-16000328","url":null,"abstract":"Japanese encephalitis (JE) is still one of the most dangerous mosquito-transmitted infections in the world, and there is no cure or set of rules for treating it. The clinical signs and progression of the infection are influenced by the pathogenicity of both the viral determinants and the host immune responses. JE can affect both fine and gross motor skills, making it difficult to perform tasks including walking, gripping, and coordinating actions. In the absence of antiviral treatment, vaccination is the only way to produce long-lasting protection against JEV infection. The disease still lacks a cure or treatment recommendations. Various global institutes such as WHO, Gavi, UNICEF etc support the JE elimination strategies along with governments of various nations. Improvements and developments were being made in the fields of Japanese encephalitis (JE) research, prevention, and treatment","PeriodicalId":334586,"journal":{"name":"Virology & Immunology Journal","volume":"26 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139361613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Various Infections and Alzheimer's Disease","authors":"Hassan Bar","doi":"10.23880/vij-16000317","DOIUrl":"https://doi.org/10.23880/vij-16000317","url":null,"abstract":"Alzheimer's disease (AD) is a major contributor to the worldwide prevalence of dementia. Extracellular-amyloid (A) senile plaques (SP) and intracellular neurofibrillary tangles (NFT) are the neuropathological hallmarks of Alzheimer's disease. Currently, it is believed that both hereditary and environmental variables interact to contribute to the pathophysiology of AD. Despite significant investments in neurological research, the precise molecular basis of AD pathogenesis remains unknown. Multiple studies point to the possibility that pathogenic microorganisms contribute to the development of AD. Microbes were formerly thought to have no connection to Alzheimer's disease, but a rising body of research suggests otherwise. Evidence that these microbes cause AD-specific cognitive and neuropathological deficits and changes is lacking, casting doubt on the hypothesis that AD is an infectious neurological illness. In addition, the gut flora may have a role in AD progression in humans.","PeriodicalId":334586,"journal":{"name":"Virology & Immunology Journal","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130860836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physiotherapy and Cardiopulmonary Rehabilitation Approaches in SARS-CoV-2 Infection","authors":"Artik Y","doi":"10.23880/vij-16000318","DOIUrl":"https://doi.org/10.23880/vij-16000318","url":null,"abstract":"An arising of infectious outbreaks lately December of 2019 has been reported as pneumonia of unknown cause appeared in Wuhan city, China which called SARS-CoV-2. Globally, 12 July 2023, there have been 767.972.961 confirmed cases of COVID-19, including 6.950.655 deaths, reported by WHO. As of 8 July 2023, a total of 13.474.185.140 vaccine doses have been administered. In 2013, the number of people has been died from cardiovascular disease more than 17.3 million and representing an increase from 1990 of 40.8%. Evaluating the effects on cardiopulmonary physiology has an important place among the parameters of the COVID-19 pandemic affecting public health. For this reason, we evaluated physiotherapy and rehabilitation approaches as a for CBRN threats and disaster risk management policies by associating cardiopulmonary physiology with the effects of the COVID-19 (SARS-CoV-2) pandemic","PeriodicalId":334586,"journal":{"name":"Virology & Immunology Journal","volume":"367 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125623330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nasopharyngeal Carcinoma (NPC) in Russia and Epstein - Barr Virus Types: Analysis of the Influence of Gender, Ethnic and Age Factors on the Virus Types Spread in NPC Patients","authors":"Gurtsevitch Ve","doi":"10.23880/vij-16000320","DOIUrl":"https://doi.org/10.23880/vij-16000320","url":null,"abstract":"Introduction: The discovery of two molecular types of Epstein-Barr virus, EBV-1 and EBV-2, with different biological properties, stimulated the search for new neoplasms associated with each type of the virus. Objective: The aim of this study was to analyze the prevalence of EBV-1 and EBV-2 in NPC patients from different climatic and geographical regions of Russia, representatives of different gender, ethnic and age groups of patients. Materials and Methods: Using nested PCR EBV types were determined in blood plasma of NPC and other non-EBV-associated tumors of the oral cavity (OTOC/EBV-) patients from the North Caucasus (NCFD) and the Central (CFD) Federal Districts of Russia. IgG and IgA antibody titers to viral capsid antigen (VCA) were determined by indirect immunofluorescence. Results: The studies carried out have shown that NPC and OTOC/EBV- patients were infected with both EBV types in roughly the same ratio. There were also no statistically significant differences in serological activities of NPC patients infected with EBV-1 or EBV-2. The prevalence of EBV-2 types 1 and 2 was not influenced by gender or ethno-geographic affiliation of NPC patients. The only difference was EBV-2 predominance in NPC patients under 60, and EBV-1 predominance in those over 60 years old. Conclusion: The absence of a predominance of one of the EBV types in NPC patients indicates that neither EBV-1 nor EBV-2 is strictly NPC-associated in Russia, and that different ethnic and climatic-geographical factors in the spread of virus types in NPC patients are not playing an essential role.","PeriodicalId":334586,"journal":{"name":"Virology & Immunology Journal","volume":"129 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115464509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel Corona Turkish Novel Protocol","authors":"Sahan Ag","doi":"10.23880/vij-16000323","DOIUrl":"https://doi.org/10.23880/vij-16000323","url":null,"abstract":"Aim: To share a novel corona treatment method that is effective on patients with the scientific community. Introduction: The new corona infection has caused a different fear all over the world, and many studies have been conducted to prolong the lives of patients who die from complications or while being treated. Materials & Methods: Among the 2000 patients who were admitted to the service(500), outpatient clinic(1420) and hospitalized in intensive care (80), 147 patients who were examined naively during the period 1.2.2021-1.4.2021 were included in the study cross-sectionally. Patients at risk of death in intensive care and pre-treatment protocols at varying rates depending on the different age. Regarding the diagnosis and treatment of the disease; Since it is known that even the effects of drugs that cause complications cause human death, it was prioritized to make the treatment plan accordingly and pay attention to the complications of these treatments. The patient, whose problems with hydroxychloroquine, favipiravir and other protocols are recovering, can lead to lung edema, intubation in the intensive care unit and subsequent death. Although the complications and mortality rate of the disease is not more than influenza, it seems possible to prevent some of the deaths. The age of patients’ distrubition 5 from 94 years old, avarage age 42 years old. drugs used in treatment planning, D vitamins single dose and zinc , tigacycline , vancomycin (renal function controlled), meropenem 1 gr (renal function controlled),enoxaparin (renal function controlled) pantoprasol , 4 gr ascorbic acid will be infused,dexamethasone , budesonide. If there is an increase in the response to antibiotherapy, ivermectine therapy, tocilisumab treatment should be added without delay. tocilisumab therapy ; tocilisumab and ivermectine treatment of patients will be consideredaccording to crp decrease. Result: The patient is treated and remains normal for three days, the patient can be discharged. There was no need for tocilizumab treatment on the patients did not use favipiravir treatment among were followed up. Longest treatment protocol is completed 21 days; shortest treatment protocol is completed 3 days. No additional complications were encountered in 800 cases treated and patient follow up completed. Discussion: While researching different treatment protocols in a new viral infection, it is a wrong practice to try new drugs rather than to cure the patients. Trying to treat patients with medications that have not been followed up and tried clearly makes more harm than normal. For this reason, it preparing protocols with known drugsare vital and not to use experimental antivirals (favipiravir, remdesivir, oseltamivir etc) that did not work in previous outbreaks.","PeriodicalId":334586,"journal":{"name":"Virology & Immunology Journal","volume":"162 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127370877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nipah Virus and Bacteria Infections: Cardiac Complications in Maternal Health","authors":"Mattapally S","doi":"10.23880/vij-16000327","DOIUrl":"https://doi.org/10.23880/vij-16000327","url":null,"abstract":"As a zoonotic virus, the nipah virus (NiV) can pass from people to animals. A novel paramyxovirus called NiV, which is related to the Hendra virus and has spread globally, has had tremendous impact on people's life. Numerous investigations have shown that NiV and SARS-CoV, the zoonotic virus that was responsible for the 2002 outbreak of severe acute respiratory syndrome, have a lot in common biologically. While NiV alone can also cause myocardial damage, pre-existing cardiovascular illness appears to be associated with worse results and an increased risk of death in individuals with the virus. Emerging infections include both newly emerging and re-emerging infections that have an increasing occurrence over the past few decades or threaten to do so. A new infectious agent entering the community, a previously unknown circulating agent being discovered, or the discovery that an infection is the true cause of a noncommunicable disease.","PeriodicalId":334586,"journal":{"name":"Virology & Immunology Journal","volume":"199 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139361616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bioactive Peptides: An Advanced Version of Antiviral and Immunomodulatory Therapeutics","authors":"Singh N","doi":"10.23880/vij-16000321","DOIUrl":"https://doi.org/10.23880/vij-16000321","url":null,"abstract":"Bioactive peptides are short chains of amino acids with certain amino acid sequences that have various therapeutic effects. These peptides emerged as new class of therapeutics as they combine special qualities including high binding affinity, superior target specificity, low toxicity, and a relatively tiny mass etc. Some bioactive peptide possess antiviral activity by targeting viral envelop and by inhibiting viral entry into the host cells. They are advantageous as they don’t exhibit viral resistance like other conventional antiviral drugs. On the other hand, some bioactive peptides have immunomodulatory effects by reducing the expression of proinflammatory molecules such as IL-6, TNF-α, and COX-2. Bioactive peptides show promise as a potential substitute for or addition to conventional antiviral and immunomodulatory medications.","PeriodicalId":334586,"journal":{"name":"Virology & Immunology Journal","volume":"148 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116598619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}